On March 8, 2021 GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on disruptive, target-directed Natural Killer (NK) cell engager immunotherapy technologies (TriKE) for cancer, reported preclinical results for its ROR1 TriKE product candidate as a prospective therapy for the treatment of prostate cancer (Press release, GT Biopharma, MAR 8, 2021, View Source [SID1234576198]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Tyrosine kinase transmembrane receptor ROR1 has recently been shown to be overexpressed on certain cancer cells, and appears to play a functional role in promoting migration/invasion and influencing the metastatic potential of various solid tumor cancers. Targeting ROR1 on cancer cells with TriKE and redirecting NK cells to attack and kill cancer cells expressing ROR1, could result in a therapeutic treatment that limits the metastatic potential and invasiveness of certain solid tumor cancers.
The ROR1 TriKE was evaluated in several preclinical models of prostate cancer, and was found to be effective at promoting NK cell killing of multiple prostate cancer cells including LnCAP, C4-2, PC-3, DU-145, VCaP and 22RV1. Significant NK cell activation and interferon gamma (IFNγ) production was also observed as a result of TriKE engagement and activation of the NK cell.
"We are pleased to report our ROR1 TriKE has passed this important preclinical milestone, and demonstrated effectiveness in promoting redirected and target-specific killing by NK cells," said Anthony J. Cataldo, GT Biopharma’s Chairman and Chief Executive Officer. "We plan to evaluate the ROR1 TriKE in additional IND-enabling preclinical studies with the goal of transitioning to a Phase I/II clinical trial."